Immuneering (IMRX) Net Cash Flow (2020 - 2024)
Historic Net Cash Flow for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$9.1 million.
- Immuneering's Net Cash Flow fell 493.85% to -$9.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$23.3 million, marking a year-over-year decrease of 7580.66%. This contributed to the annual value of -$23.3 million for FY2024, which is 7580.66% down from last year.
- Per Immuneering's latest filing, its Net Cash Flow stood at -$9.1 million for Q4 2024, which was down 493.85% from -$14.5 million recorded in Q3 2024.
- Over the past 5 years, Immuneering's Net Cash Flow peaked at $56.7 million during Q3 2021, and registered a low of -$36.0 million during Q3 2023.
- Its 5-year average for Net Cash Flow is $71503.9, with a median of -$5.0 million in 2021.
- In the last 5 years, Immuneering's Net Cash Flow surged by 172338.02% in 2021 and then tumbled by 21231.24% in 2023.
- Over the past 5 years, Immuneering's Net Cash Flow (Quarter) stood at $31.5 million in 2020, then plummeted by 201.74% to -$32.0 million in 2021, then soared by 88.2% to -$3.8 million in 2022, then crashed by 128.37% to -$8.6 million in 2023, then fell by 4.94% to -$9.1 million in 2024.
- Its Net Cash Flow stands at -$9.1 million for Q4 2024, versus -$14.5 million for Q3 2024 and -$6.6 million for Q2 2024.